Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of diagnosis of liver steatosis

A technology of hepatic steatosis and steatosis, which is applied in the field of diagnosis of hepatic steatosis, and can solve the problems of undisclosed and explicit denials

Pending Publication Date: 2021-05-14
BIOPREDICTIVE +1
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The option to use BMI and bilirubin is not explicitly disclosed in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of diagnosis of liver steatosis
  • Method of diagnosis of liver steatosis
  • Method of diagnosis of liver steatosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0208] Example 1. Overview

[0209] METHODS: Five different subgroups of 2997 biopsied patients were evaluated for test construction and validation, and four for the prevalence of steatosis in a target population at increased risk of steatosis. The performance of SteatoTest-2 was compared to the reference test using a non-inferiority test (0.10 cut-off) and the Lin coefficient of agreement.

[0210] Results: The AUROC of SteatoTest-2 was not worse than the reference test (P<0.001). AUROC differed according to subgroup and prevalence of steatosis in SteatoTest-2 and reference test, which were 0.772 (95% CI 0.713-0.820) vs 0.786 (0.729-0.832) in 2997 biopsy cases, respectively, and 0.822 (0.810-0.834) vs 0.868 (0.858-0.878) among 5776 cases (including healthy subjects without steatosis risk factors as controls). Lin coefficients were highly consistent (P<0.001), ranging from 0.74 (0.74-0.74) in putative NAFLD to 0.91 (0.89-0.93) in constructed subgroups.

[0211] Conclusion...

Embodiment 2

[0212] Example 2. Patients and methods

[0213] Research design

[0214] Prospective analysis of patient subgroups ( figure 1)'s research is to construct a simplified new SteatoTest-2 that is highly consistent with and not inferior to the first generation SteatoTest, with higher applicability in the general population and less risk of false positives lower. SteatoTest-2 was also evaluated based on paired biopsies before and after treatment in the prospective trial of slonertin for the treatment of NASH.

[0215] The second objective was to evaluate the performance of SteatoTest-2 when used in combination with NashTest-2 (as disclosed in WO2018050804) in non-invasive algorithms replicating histological NASH algorithms (CRN or FLIP) which require The presence of steatosis is used to diagnose NASH (Poynard et al., Eur J Gastroenterol Hepatol. 2018; 30:384-391; Poynard et al., Eur J Gastroenterol Hepatol. 2018; 30:569-577).

[0216] Variability in the SteatoTest-2 AUROC wa...

Embodiment 3

[0236] Example 3. Results

[0237] Characteristics of subjects included

[0238] A total of 2997 biopsied and histologically scored patients were evaluated by the SAF scoring system. Although the characteristics of the included subjects have been published in previous publications, the value of this integrated database lies in its broad characterization, which allows the robustness of blood tests to be assessed in terms of variability factors. The IQR for age ranged from 34 to 61 years. The prevalence of histologic steatosis ranged from 7.3% to 24.5%, NASH ranged from 13.7% to 100%, cirrhosis ranged from 0% to 42.6%, and the prevalence of T2 diabetes ranged from 7.5% to 70.8% The range of obesity (BMI ≥ 30) is 13.6% to 100%. The subgroup of obese subjects was younger, had a higher percentage of women, and had a lower prevalence of advanced fibrosis than other subgroups.

[0239] New SteatoTest-2

[0240] Unlike SteatoTest, SteatoTest-2 does not include BMI or total bili...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to new methods for assessing the presence of nonalcoholic steatohepatitis (steatosis) in a patient, using functions combining biological markers without bilirubin and Body Mass Index being used as markers in the function.

Description

technical field [0001] The present invention relates to a new non-invasive quantitative test that allows the detection of hepatic steatosis and helps to identify subjects at risk of non-alcoholic fatty liver disease (NAFLD), especially those suffering from non-alcoholic fatty liver disease Subjects with acute hepatitis (NASH) or fibrosis. Background technique [0002] Fatty liver is a reversible disease in which massive triglyceride fat vacuoles accumulate in hepatocytes through the process of steatosis. [0003] Nonalcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, which occurs when fat deposits in the liver (steatosis) for reasons other than excessive alcohol consumption. NAFLD is the most common liver disease in developed countries. NAFLD is a disease often associated with elements of the metabolic syndrome. [0004] While the liver can retain fat without disrupting liver function, it can also develop nonalcoholic steatohepatitis (NASH), a state...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G16H50/20G16H50/30G01N33/68
CPCG01N33/6893G01N2800/085G16H50/20G16H50/30G01N33/728
Inventor T·波纳德
Owner BIOPREDICTIVE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com